Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0U5NU
|
|||
| Former ID |
DIB016533
|
|||
| Drug Name |
GLENVASTATIN
|
|||
| Synonyms |
HR-780; Glenvastatin; [4(R),6(S),(E)]-6-[2-[4-(4-Fluorophenyl)-2-isopropyl-6-phenyl-3-pyridyl]vinyl]-4-hydroxytetrahydropyran-2-one
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hyperlipidaemia [ICD-11: 5C80; ICD-10: E78.5] | Discontinued in Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H26FNO3
|
|||
| Canonical SMILES |
CC(C)C1=C(C(=CC(=N1)C2=CC=CC=C2)C3=CC=C(C=C3)F)C=CC4CC(CC(=O)O4)O
|
|||
| InChI |
1S/C27H26FNO3/c1-17(2)27-23(13-12-22-14-21(30)15-26(31)32-22)24(18-8-10-20(28)11-9-18)16-25(29-27)19-6-4-3-5-7-19/h3-13,16-17,21-22,30H,14-15H2,1-2H3/b13-12+/t21-,22-/m1/s1
|
|||
| InChIKey |
LJIZUXQINHXGAO-ITWZMISCSA-N
|
|||
| CAS Number |
CAS 122254-45-9
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:5597
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HMG-CoA reductase (HMGCR) | Target Info | Inhibitor | [2], [3] |
| BioCyc | Superpathway of geranylgeranyldiphosphate biosynthesis I (via mevalonate) | |||
| Superpathway of cholesterol biosynthesis | ||||
| Mevalonate pathway | ||||
| KEGG Pathway | Terpenoid backbone biosynthesis | |||
| Metabolic pathways | ||||
| Biosynthesis of antibiotics | ||||
| AMPK signaling pathway | ||||
| Bile secretion | ||||
| NetPath Pathway | IL5 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| TSH Signaling Pathway | ||||
| Panther Pathway | Cholesterol biosynthesis | |||
| Pathwhiz Pathway | Steroid Biosynthesis | |||
| WikiPathways | Statin Pathway | |||
| Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | ||||
| Activation of Gene Expression by SREBP (SREBF) | ||||
| SREBF and miR33 in cholesterol and lipid homeostasis | ||||
| Integrated Breast Cancer Pathway | ||||
| SREBP signalling | ||||
| Cholesterol Biosynthesis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001230) | |||
| REF 2 | Bile acid derived HMG-CoA reductase inhibitors. Biochim Biophys Acta. 1994 Nov 29;1227(3):137-54. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.